Elevance Health (ELV) Q1 2026 Earnings Transcript

Elevance Health raised full-year 2026 adjusted EPS guidance to at least $26.75 after posting Q1 adjusted EPS of $12.58, helped by better-than-expected claims experience and about $1 per share of nonrecurring investment income. Operating revenue rose 1.5% to $49.5 billion, while membership increased nearly 200,000 sequentially to 45.4 million; the company also recorded a $935 million CMS-related accrual and reaffirmed at least $5.5 billion of operating cash flow. Management highlighted improving Medicaid and Medicare trends, over $1 billion of AI/digital investment, and continued share repurchases, with at least $2.3 billion targeted in 2026.

Analysis

The clean read-through is that Elevance is not just defending margin; it is actively reshaping the earnings mix toward less cyclical, more controllable revenue streams. The real second-order benefit is that higher ACA bronze penetration and employer consolidation make the book less dependent on medical-cost normalization and more dependent on product design, pricing discipline, and admin/clinical execution — all areas where scale matters and smaller managed-care peers should struggle to keep up.

The CMS accrual is the key overhang, but the market is likely mispricing its duration more than its size. The immediate issue is not the accounting charge; it is whether the process forces management to hold more capital against a headline risk event while simultaneously buying back stock at >$300. If the matter resolves without a cash surprise, the combination of a raised guide and an aggressive repurchase pace creates a mechanical EPS floor into 2026-2027, especially if operating trends stay even modestly favorable.

The bigger strategic tell is Carelon: management is effectively admitting that integrated medical-pharmacy-home-based care is becoming the growth engine, while the insurance book becomes the funding base. That is structurally bullish for vendors that help with automation, data integration, and care navigation, but bearish for standalone point-solution vendors and any PBM business that cannot prove tangible total-cost-of-care savings. The risk is that Medicaid rate relief lags the underlying trend, which would push pressure into 2027 and could force more state exits; that is a months-to-quarters issue, not a days issue.

Contrarian view: the stock’s strength may already reflect the obvious EPS raise, but not the less obvious mix improvement in commercial and ACA. The market may underappreciate that a sustained bronze shift and near-100% large-account renewal behavior can offset some Medicaid drag without heroic claims assumptions. If that persists through midyear, the setup is less about a one-quarter beat and more about a re-rating of durability.

Key Decisions for Investors

• Long ELV into the next 3-6 months as a quality defensive compounder; the setup is attractive if the CMS process remains non-cash or delayed, with downside limited by buybacks and upside from guide credibility and mix improvement.
• Sell downside via ELV put spreads 2-4 months out to monetize the elevated headline risk around CMS while keeping exposure to continued execution; best if implied vol is pricing a larger cash penalty than management’s current accrual suggests.
• Pair trade: long ELV / short UNH over the next 1-2 quarters if you want managed-care exposure with lower regulatory noise and better visible 2026-2027 EPS comp; ELV has more controllable catalysts while the short leg carries more operational uncertainty.
• Long healthcare IT / automation beneficiaries on the AI and workflow theme (e.g., VEEV or TDOC selectively) against legacy admin-heavy service names over 6-12 months, because managed care is moving budget toward integration and productivity rather than pure headcount growth.
• Avoid chasing pure-play PBM exposure; if Carelon Rx keeps proving medical-cost savings, the winners are integrated platforms like ELV, while weaker standalones face margin compression and pricing transparency pressure over the next 12 months.